439
|
1925 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
Inositol 1,4,5-trisphosphate
|
in pilocarpine model
|
|
1471196
|
Status epilepticus
|
440
|
1940 |
Inositol 1,4,5-trisphosphate
|
|
interacts (colocalizes) with
|
ITPR1
|
in pilocarpine model
|
|
1648604
|
Neurological
Status epilepticus
|
4,660
|
46388 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
in pancreas, in pancreatic islets
|
46390 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
calcium-mediated signaling
|
in pancreas, in pancreatic islets
|
46447 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
ITPR
|
in pancreas, in pancreatic islets; via binding to the receptor
|
|
21966580
|
Diabetes mellitus, type II
Schizophrenia
Insulin resistance
|
4,686
|
46621 |
PLCB
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
in pancreas, in pancreatic islet beta cells
|
46623 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
ITPR
|
in pancreas, in pancreatic islet beta cells; via binding of IP3 to its receptor
|
|
24114586
|
Bipolar disorder
Diabetes mellitus, type II
Schizophrenia
Insulin resistance
|
5,058
|
49756 |
PLCB2
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
8245028
|
Neurological
|
5,059
|
49755 |
Inositol 1,4,5-trisphosphate
|
|
interacts (colocalizes) with
|
IP3R receptor complex
|
|
49774 |
Inositol 1,4,5-trisphosphate
|
|
is_part_of
|
IP3-IP3R receptor complex
|
|
|
16919684
|
Neurological
|
5,441
|
53112 |
LRP5
|
|
affects_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
12509515
|
Diabetes mellitus, type II
Insulin resistance
|
6,492
|
61981 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
62203 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
62346 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
calcium-mediated signaling
|
|
|
15471909
|
Metabolic
|
6,517
|
61973 |
Lithium
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
62095 |
Inositol
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
62105 |
Inositol 1,4,5-trisphosphate
|
|
decreases_activity of
|
autophagy
|
|
|
16186256
|
Metabolic
|
7,296
|
71673 |
SYNJ1
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
15474001
|
Diabetes mellitus, type II
Insulin resistance
Ciliopathy
|
7,420
|
72888 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
72891 |
Inositol 1,4,5-trisphosphate
|
|
affects_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
72892 |
Inositol 1,4,5-trisphosphate
|
|
increases_quantity of
|
Inositol 3,4,5,6-tetrakisphosphate
|
|
72893 |
Inositol 1,4,5-trisphosphate
|
|
increases_quantity of
|
Inositol 1,2,3,4,5,6-hexakisphosphate
|
|
72895 |
Inositol 1,4,5-trisphosphate
|
|
increases_quantity of
|
5-PP-InsP5
|
|
72896 |
Inositol 1,4,5-trisphosphate
|
|
increases_quantity of
|
Bisdiphosphoinositol tetrakisphosphate
|
|
|
26862218
|
Diabetes mellitus, type II
Insulin resistance
|
9,120
|
96845 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
25960051
|
Arterial calcification, generalized, of infancy, 1
|
11,358
|
114099 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
Calcium-release channel
|
when activated by IP3, releasing Ca+ from ER lumen into cytoplasm
|
114106 |
Fas signaling pathway
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
via the activation of phospholipase C-gamma1, and the subsequent enhanced Ca2+ release from IP3 receptors
|
114107 |
Inositol 1,4,5-trisphosphate
|
|
interacts (colocalizes) with
|
ITPR
|
serving as second messenger
|
114108 |
Inositol 1,4,5-trisphosphate
|
|
is_part_of
|
ITPR-IP3 complex
|
localized in ER membrane; Fas-signaling-induced apoptosis involves the increase of IP3 production, via the activation of PLCG1
|
114109 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
calcium ion import into cytosol
|
from ER lumen into cytosol; the activation of PLCG1 enhanced Ca2+ release from IP3 receptors, creating an increased intracellar free calcium level; IP3 acts as second messenger
|
114110 |
PLCG1
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
in cytosol; PLCG cleaves PIP2 into DAG and IP3
|
114111 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
ITPR
|
localized in ER membrane; resulting in an enhanced Ca2+ release from IP3 receptors
|
114129 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
tricarboxylic acid cycle
|
in mitochondria; by increasing mitochondrial matrix Ca2+ concentration
|
|
19144519
|
Metabolic
|
11,492
|
114705 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
ITPr
|
generated by phospholipase C (PLC) in response to the activation of various G-protein-coupled receptors (GPCRs) or of tyrosine kinase-linked receptors
|
114791 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
second-messenger-mediated signaling
|
Ca2+-release through IP3Rs requires binding of the second messenger IP3
|
114812 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
18478527
|
Alzheimer disease
|
11,493
|
114722 |
ATP
|
|
increases_activity of
|
Inositol 1,4,5-trisphosphate
|
ATP alone was not sufficient to open the IP3-gated channel, but addition of ATP or non-hydrolyzable ATP analogs in the presence of IP3 increased the frequency and average duration of channel openings
|
|
7686381
|
Metabolic
|
11,523
|
114998 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
PIP2 is the precursor of inositol triphosphate (IP3) resulting from cleavage by phospholipase C (PLC)
|
114999 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
calcium ion export from endoplasmic reticulum
|
|
115002 |
PLC
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
when PLC is activated
|
115060 |
Inositol 1,4,5-trisphosphate
|
|
interacts (colocalizes) with
|
ITPR
|
|
115061 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
Calcium-release channel
|
increased concentration of IP3 triggers the release of Ca2+ from intracellular stores after binding to IP3 receptors
|
|
23798435
|
Metabolic
|
11,762
|
116467 |
Inositol 1,4,5-trisphosphate
|
|
increases_activity of
|
calcium ion import into cytosol
|
releasing Ca2+ from the intracellular stores through IP3 receptor channels
|
|
19422456
|
Metabolic
|
14,301
|
134933 |
PLCG2-PRKCA complex
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
16923831
|
Metabolic
|
15,346
|
145088 |
Verapamil
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
inducing the degradation of aggregate-prone proteins
|
145089 |
Loperamide
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
inducing the degradation of aggregate-prone proteins
|
145090 |
Clonidine
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
inducing the degradation of aggregate-prone proteins
|
145091 |
CAST
|
|
decreases_quantity of
|
Inositol 1,4,5-trisphosphate
|
inducing the degradation of aggregate-prone proteins
|
145092 |
Inositol 1,4,5-trisphosphate
|
|
decreases_activity of
|
autophagosome assembly
|
inducing the degradation of aggregate-prone proteins
|
|
|
Alzheimer disease
|